Blog
Examine finds bebtelovimab remedy lacks efficacy in sufferers contaminated with SARS-CoV-2 Omicron subvariants
13
Dec
Dec
In a latest research posted to the medRxiv* preprint server, researchers assessed the affect of bebtelovimab (BEB) monoclonal antibody (MAb) within the remedy of high-risk extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant-infected sufferers. Examine: Lack of effectiveness of Bebtelovimab Monoclonal Antibody Amongst Excessive-Threat Sufferers with SARS-Cov-2 Omicron Throughout BA.2, BA.2.12.1 and BA.5 Subvariants […]